The Effect of Coenzyme Q10 on Hearing and Tinnitus Characteristics of Chronic Tinnitus Patients
Launched by UNIVERSITY HOSPITAL, ANTWERP · Feb 2, 2015
Trial Information
Current as of April 28, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • chronic non-pulsatile tinnitus \> 3 months
- • tinnitus has a clear otological cause
- • age \> 18 years
- Exclusion Criteria:
- • pulsatile tinnitus
- • persons who take already Q10
- • pregnancy
- • cervical tinnitus
- • holocranial tinnitus
- • depression
- • mental of neurological disorders
- • history of chemotherapy
- • middle ear diseases
About University Hospital, Antwerp
University Hospital Antwerp is a leading academic medical center dedicated to advancing healthcare through innovative research and clinical trials. With a strong emphasis on patient-centered care, the hospital fosters a collaborative environment that integrates cutting-edge scientific inquiry with state-of-the-art medical practices. As a prominent sponsor of clinical trials, University Hospital Antwerp is committed to enhancing medical knowledge and improving treatment outcomes across a wide range of specialties, leveraging its expertise to contribute significantly to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Edegem, Antwerp, Belgium
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials